Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
NCT05970666Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Xiamen University. Started Nov 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05970666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970666.